C-Path, CDISC Develop Standard to Represent Data for Animal Rule Studies TUCSON, Ariz. and AUSTIN, Texas, October 15, 2019 — The Critical Path Institute (C-Path) and CDISC are pleased to announc
October 9, 2019 On September 25th, the FDA published a Personal Viewpoint in the American Journal of Transplantation
The Critical Path for Parkinson’s Consortium (CPP) welcomes PMD Alliance as newest member The Critical Path for Parkinson’s Consortium (CPP) is thrilled to welcome the PMD Alliance (Parkinson & Movement Disorder Al
September 25, 2019 Assessment of Long-term Neurodevelopmental Outcome Following Trials of Medicinal Products in Newborn Infants
September 23, 2019 Development of a Neonatal Adverse Event Severity Scale Through a Delphi Consensus Approach
September 23, 2019 Enabling efficient use of digital health technologies to support Parkinson’s disease drug development through precompetitive collaboration
September 20, 2019 The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease Stephenson D, Hill D, Cedarbaum JM, Tome M, Vamvakas S, Romero K, Conrado DJ, Dexter DT, Seibyl J, Jennings D, Nicholas T...
Innovative Data and Analytics Platform to Accelerate Drug Development for Rare Diseases Launched by C-Path and NORD through an FDA grant, the goal of the new platform is to accelerate the development of cures by addres
C-Path’s Martha A. Brumfield Named Arizona Bioscience Leader of the Year CHANDLER, Ariz., Sept. 18, 2019 — The Arizona Bioindustry Association (AZBio) today announced that Martha A. Brumf
September 13, 2019 Symptoms of Major Depressive Disorder Scale: Performance of a Novel Patient-Reported Symptom Measure